DiaMedica Therapeutics (DMAC) Competitors $3.51 -0.03 (-0.85%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$3.84 +0.33 (+9.40%) As of 04:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DMAC vs. CVAC, XNCR, PRTA, REPL, ABUS, VECT, KALV, AVBP, TRVI, and RCKTShould you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include CureVac (CVAC), Xencor (XNCR), Prothena (PRTA), Replimune Group (REPL), Arbutus Biopharma (ABUS), VectivBio (VECT), KalVista Pharmaceuticals (KALV), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical products" industry. DiaMedica Therapeutics vs. CureVac Xencor Prothena Replimune Group Arbutus Biopharma VectivBio KalVista Pharmaceuticals ArriVent BioPharma Trevi Therapeutics Rocket Pharmaceuticals CureVac (NASDAQ:CVAC) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment. Which has better earnings & valuation, CVAC or DMAC? DiaMedica Therapeutics has lower revenue, but higher earnings than CureVac. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCureVac$543.28M1.33-$281.58M$0.823.94DiaMedica TherapeuticsN/AN/A-$19.38M-$0.60-5.85 Do insiders & institutionals have more ownership in CVAC or DMAC? 17.3% of CureVac shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 7.2% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media prefer CVAC or DMAC? In the previous week, CureVac had 21 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 23 mentions for CureVac and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.43 beat CureVac's score of 0.29 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment CureVac Neutral DiaMedica Therapeutics Neutral Which has more risk and volatility, CVAC or DMAC? CureVac has a beta of 2.48, indicating that its stock price is 148% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Is CVAC or DMAC more profitable? CureVac has a net margin of 20.72% compared to DiaMedica Therapeutics' net margin of 0.00%. CureVac's return on equity of 21.98% beat DiaMedica Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CureVac20.72% 21.98% 15.72% DiaMedica Therapeutics N/A -43.67%-40.81% Does the MarketBeat Community prefer CVAC or DMAC? DiaMedica Therapeutics received 68 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 63.09% of users gave DiaMedica Therapeutics an outperform vote while only 55.32% of users gave CureVac an outperform vote. CompanyUnderperformOutperformCureVacOutperform Votes2655.32% Underperform Votes2144.68% DiaMedica TherapeuticsOutperform Votes9463.09% Underperform Votes5536.91% Do analysts rate CVAC or DMAC? CureVac presently has a consensus target price of $10.00, indicating a potential upside of 209.60%. DiaMedica Therapeutics has a consensus target price of $8.00, indicating a potential upside of 127.92%. Given CureVac's higher possible upside, equities research analysts plainly believe CureVac is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCureVac beats DiaMedica Therapeutics on 10 of the 17 factors compared between the two stocks. Remove Ads Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAC vs. The Competition Export to ExcelMetricDiaMedica TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$150.43M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-6.276.7921.7217.82Price / SalesN/A225.96376.8894.61Price / CashN/A65.6738.1534.64Price / Book2.605.866.474.00Net Income-$19.38M$141.86M$3.20B$247.23M7 Day Performance-5.14%4.50%2.86%1.45%1 Month Performance-39.17%-12.65%-8.55%-6.24%1 Year Performance48.10%-11.06%10.58%0.60% DiaMedica Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMACDiaMedica Therapeutics1.3186 of 5 stars$3.51-0.8%$8.00+127.9%+46.9%$150.43MN/A-6.2720Short Interest ↑Gap DownCVACCureVac3.3393 of 5 stars$2.65+2.3%$10.00+277.4%+21.9%$593.28M$543.28M4.82880Earnings ReportUpcoming EarningsShort Interest ↑XNCRXencor3.3808 of 5 stars$8.37-3.7%$34.38+310.7%-52.6%$589.77M$110.49M-2.62280PRTAProthena3.5303 of 5 stars$10.84-0.2%$55.00+407.4%-56.4%$583.49M$135.16M-4.71130High Trading VolumeREPLReplimune Group3.591 of 5 stars$7.49+0.4%$19.43+159.4%+8.3%$576.84MN/A-2.44210ABUSArbutus Biopharma1.768 of 5 stars$3.01-6.8%$5.50+82.7%+6.4%$576.36M$6.17M-7.0090Positive NewsVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030News CoverageHigh Trading VolumeKALVKalVista Pharmaceuticals4.1901 of 5 stars$11.50+7.4%$24.83+115.9%+2.4%$571.73MN/A-3.16100Gap DownHigh Trading VolumeAVBPArriVent BioPharma1.1368 of 5 stars$16.61+1.2%$39.00+134.8%+9.6%$565.01MN/A-6.4640News CoveragePositive NewsGap DownTRVITrevi Therapeutics3.3949 of 5 stars$5.78-4.5%$17.56+203.8%+120.6%$558.82MN/A-13.1420RCKTRocket Pharmaceuticals4.62 of 5 stars$5.19+1.4%$43.00+728.5%-72.8%$553.41MN/A-1.89240Insider TradeNews CoverageGap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies CureVac Alternatives Xencor Alternatives Prothena Alternatives Replimune Group Alternatives Arbutus Biopharma Alternatives VectivBio Alternatives KalVista Pharmaceuticals Alternatives ArriVent BioPharma Alternatives Trevi Therapeutics Alternatives Rocket Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAC) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
